deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06976476

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Prospective Randomized Phase II Study Evaluating Efficacy and Safety of IgPro20 as Infection Prophylaxis in Patients With Multiple Myeloma and Hypogammaglobulinemia Receiving Therapy With a Bispecific Monoclonal Antibody (BsAbs)

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Hypogammaglobulinemia Hypogammaglobulinemia, Acquired Multiple Myeloma
Interventions IgPro20
Updated 5 times since 2025 Last updated: Mar 10, 2026 Started: May 8, 2025 Primary completion: May 8, 2029 Completion: May 8, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hypogammaglobulinemia and Hypogammaglobulinemia, Acquired and is currently actively recruiting participants. Memorial Sloan Kettering Cancer Center leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshotRecruiting~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshotRecruiting~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – ~Mar 2026 · 59 days · monthly snapshotRecruiting~Mar 2026 – present · 4 months · monthly snapshotRecruiting

Change History

5 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE2

  2. Jan 2026 — Mar 2026 [monthly]

    Recruiting PHASE2

  3. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  4. Sep 2025 — Dec 2025 [monthly]

    Recruiting PHASE2

  5. Jun 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

    First recorded

May 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations